LEXARIA BIOSCIENCE CORP. Net Income (Loss) Available to Common Stockholders, Basic
LEXARIA BIOSCIENCE CORP. (LEXX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$1.76 million for the 3-month period ending 2022-11-30, per its 10-Q/A filed 2023-01-18.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-01-18
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for the quarter ending 2022-11-30 was -$1.76M.
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for the quarter ending 2022-08-31 was -$1.47M.
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for the quarter ending 2022-05-31 was -$2.38M.
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for the quarter ending 2022-02-28 was $1.43M.
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for fiscal 2022 was -$7.27M.
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for fiscal 2021 was -$4.03M.
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for fiscal 2020 was -$3.93M.
- LEXARIA BIOSCIENCE CORP. net income (loss) available to common stockholders, basic for fiscal 2019 was -$4.10M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-11-30 | -$1.76M 10-Q/A · filed 2023-01-18 | -$3.22M derived: sum of 2 quarters · filed 2023-01-18 | -$5.61M derived: sum of 3 quarters · filed 2023-01-18 | -$4.18M derived: sum of 4 quarters · filed 2023-01-18 | ||||
| 2022-08-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | -$3.85M derived: sum of 2 quarters · filed 2022-11-28 | -$2.42M derived: sum of 3 quarters · filed 2022-11-28 | -$7.27M 10-K · filed 2022-11-28 | ||||
| 2022-05-31 | -$2.38M 10-Q · filed 2022-07-14 | -$957.15K derived: sum of 2 quarters · filed 2022-07-14 | -$5.80M 10-Q · filed 2022-07-14 | -$4.13M derived: sum of 4 quarters · filed 2023-01-18 | ||||
| 2022-02-28 | $1.43M 10-Q · filed 2022-04-11 | $3.42M 10-Q · filed 2022-04-11 | -$1.75M derived: sum of 3 quarters · filed 2023-01-18 | -$4.30M derived: sum of 4 quarters · filed 2023-01-18 | ||||
| 2021-11-30 | -$1.99M 10-Q/A · filed 2023-01-18 | -$3.17M derived: sum of 2 quarters · filed 2023-01-18 | -$5.73M derived: sum of 3 quarters · filed 2023-01-18 | -$6.13M derived: sum of 4 quarters · filed 2023-01-18 | ||||
| 2021-08-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | -$3.74M derived: sum of 2 quarters · filed 2022-11-28 | -$4.14M derived: sum of 3 quarters · filed 2022-11-28 | -$4.03M 10-K · filed 2022-11-28 | ||||
| 2021-05-31 | -$2.56M 10-Q · filed 2022-07-14 | -$2.96M derived: sum of 2 quarters · filed 2022-07-14 | -$2.85M 10-Q · filed 2022-07-14 | -$4.37M derived: sum of 4 quarters · filed 2022-07-14 | ||||
| 2021-02-28 | -$404.11K 10-Q · filed 2022-04-11 | $404.11K 10-Q · filed 2021-04-14 | $291.92K 10-Q · filed 2022-04-11 | -$291.92K 10-Q · filed 2021-04-14 | -$1.82M derived: sum of 3 quarters · filed 2022-04-11 | -$3.18M derived: sum of 4 quarters · filed 2022-04-11 | ||
| 2020-11-30 | -$696.03K 10-Q · filed 2022-01-14 | -$1.41M derived: sum of 2 quarters · filed 2022-01-14 | -$2.77M derived: sum of 3 quarters · filed 2022-01-14 | -$3.72M derived: sum of 4 quarters · filed 2022-01-14 | ||||
| 2020-08-31 | -$714.96K 10-Q · filed 2021-04-14 | -$2.08M derived: sum of 2 quarters · filed 2021-07-15 | -$3.03M derived: sum of 3 quarters · filed 2021-07-15 | -$3.93M 10-K · filed 2021-11-29 | ||||
| 2020-05-31 | -$1.36M 10-Q · filed 2021-07-15 | -$2.31M derived: sum of 2 quarters · filed 2021-07-15 | -$3.11M 10-Q · filed 2021-07-15 | -$3.22M 10-Q · filed 2020-06-29 | -$4.30M derived: sum of 4 quarters · filed 2021-07-15 | |||
| 2020-02-29 | -$950.34K 10-Q · filed 2021-04-14 | -$1.86M 10-Q · filed 2021-04-14 | -$2.94M derived: sum of 3 quarters · filed 2021-04-14 | -$4.11M derived: sum of 4 quarters · filed 2021-04-14 | ||||
| 2019-11-30 | -$907.31K 10-Q · filed 2021-04-14 | -$1.99M derived: sum of 2 quarters · filed 2021-04-14 | -$3.16M derived: sum of 3 quarters · filed 2021-04-14 | -$4.31M derived: sum of 4 quarters · filed 2021-04-14 | ||||
| 2019-08-31 | -$1.08M 10-Q · filed 2020-06-29 | -$2.25M derived: sum of 2 quarters · filed 2020-06-29 | -$3.40M derived: sum of 3 quarters · filed 2020-06-29 | -$4.10M 10-K · filed 2020-10-15 | ||||
| 2019-05-31 | -$1.17M 10-Q · filed 2020-06-29 | -$1.18M 10-Q · filed 2019-07-08 | -$2.32M derived: sum of 2 quarters · filed 2020-06-29 | -$3.02M 10-Q · filed 2020-06-29 | -$4.25M derived: sum of 4 quarters · filed 2020-06-29 | |||
| 2019-02-28 | -$1.15M 10-Q · filed 2020-06-29 | -$1.85M 10-Q · filed 2020-04-03 | -$3.08M derived: sum of 3 quarters · filed 2020-06-29 | -$6.50M derived: sum of 4 quarters · filed 2020-06-29 | ||||
| 2018-11-30 | -$701.39K 10-Q · filed 2020-06-29 | -$1.93M derived: sum of 2 quarters · filed 2020-06-29 | -$5.35M derived: sum of 3 quarters · filed 2020-06-29 | -$6.73M derived: sum of 4 quarters · filed 2020-06-29 | ||||
| 2018-08-31 | -$1.23M derived: 10-Q 12 month − 10-Q 9 month · filed 2020-01-09 | -$4.65M derived: sum of 2 quarters · filed 2020-01-09 | -$6.03M derived: sum of 3 quarters · filed 2020-01-09 | -$6.61M 10-Q · filed 2020-01-09 | -$6.60M 10-K · filed 2018-11-14 | |||
| 2018-05-31 | -$3.42M 10-Q · filed 2019-07-08 | -$4.80M derived: sum of 2 quarters · filed 2019-07-08 | -$5.38M 10-Q · filed 2019-07-08 | -$6.07M derived: sum of 4 quarters · filed 2019-07-08 | ||||
| 2018-02-28 | -$1.38M 10-Q · filed 2019-04-15 | -$1.96M 10-Q · filed 2019-04-15 | -$2.64M derived: sum of 3 quarters · filed 2019-04-15 | -$2.98M derived: sum of 4 quarters · filed 2019-04-15 | ||||
| 2017-11-30 | -$578.71K 10-Q · filed 2018-01-12 | -$1.27M derived: sum of 2 quarters · filed 2018-11-14 | -$1.60M derived: sum of 3 quarters · filed 2018-11-14 | -$2.05M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-08-31 | -$686.92K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-14 | -$1.03M derived: sum of 2 quarters · filed 2018-11-14 | -$1.47M derived: sum of 3 quarters · filed 2018-11-14 | -$1.87M 10-K · filed 2018-11-14 | ||||
| 2017-05-31 | -$339.13K 10-Q · filed 2018-07-13 | -$786.91K derived: sum of 2 quarters · filed 2018-07-13 | -$1.18M 10-Q · filed 2018-07-13 | -$1.50M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-02-28 | -$447.78K 10-Q · filed 2018-04-12 | -$843.23K 10-Q · filed 2018-04-12 | -$1.16M derived: sum of 3 quarters · filed 2018-11-14 | -$1.42M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2016-11-30 | -$395.44K 10-Q · filed 2018-01-12 | -$709.88K derived: sum of 2 quarters · filed 2018-11-14 | -$967.91K derived: sum of 3 quarters · filed 2018-11-14 | -$1.23M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2016-08-31 | -$314.43K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-14 | -$572.46K derived: sum of 2 quarters · filed 2018-11-14 | -$832.30K derived: sum of 3 quarters · filed 2018-11-14 | -$1.21M 10-K · filed 2018-11-14 | ||||
| 2016-05-31 | -$258.03K 10-Q · filed 2017-07-14 | -$517.87K derived: sum of 2 quarters · filed 2017-07-14 | -$900.34K 10-Q · filed 2017-07-14 | -$1.42M derived: sum of 4 quarters · filed 2017-07-14 | ||||
| 2016-02-29 | -$259.84K 10-Q · filed 2017-04-14 | -$642.31K 10-Q · filed 2017-04-14 | -$1.16M derived: sum of 3 quarters · filed 2017-04-14 | -$1.63M derived: sum of 4 quarters · filed 2017-04-14 | ||||
| 2015-11-30 | -$382.47K 10-Q · filed 2017-01-13 | -$898.30K derived: sum of 2 quarters · filed 2017-01-13 | -$1.37M derived: sum of 3 quarters · filed 2017-01-13 | -$1.81M derived: sum of 4 quarters · filed 2017-01-13 | ||||
| 2015-08-31 | -$515.83K derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-29 | -$983.34K derived: sum of 2 quarters · filed 2016-11-29 | -$1.42M derived: sum of 3 quarters · filed 2016-11-29 | -$1.77M 10-K · filed 2016-11-29 | ||||
| 2015-05-31 | -$467.51K 10-Q · filed 2016-07-13 | -$907.42K derived: sum of 2 quarters · filed 2016-07-13 | -$1.25M 10-Q · filed 2016-07-13 | -$1.25M derived: sum of 4 quarters · filed 2016-07-13 | ||||
| 2015-02-28 | -$439.92K 10-Q · filed 2016-04-13 | -$787.16K 10-Q · filed 2016-04-13 | -$787.16K derived: sum of 3 quarters · filed 2016-04-13 | -$787.16K derived: sum of 4 quarters · filed 2016-04-13 | ||||
| 2014-11-30 | -$347.25K 10-Q · filed 2016-01-08 | -$347.25K derived: sum of 2 quarters · filed 2016-01-08 | -$347.25K derived: sum of 3 quarters · filed 2016-01-08 | -$347.25K derived: sum of 4 quarters · filed 2016-01-08 | ||||
| 2014-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-11-27 | $0.00 derived: sum of 2 quarters · filed 2015-11-27 | $0.00 derived: sum of 3 quarters · filed 2015-11-27 | $0.00 10-K · filed 2015-11-27 | ||||
| 2014-05-31 | $0.00 10-Q · filed 2015-07-14 | $0.00 derived: sum of 2 quarters · filed 2015-07-14 | $0.00 10-Q · filed 2015-07-14 | |||||
| 2014-02-28 | $0.00 10-Q · filed 2015-04-14 | $0.00 10-Q · filed 2015-04-14 | ||||||
| 2013-11-30 | -$75.47K 10-Q · filed 2015-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |